SOMATOSTATIN ANALOGUE LANREOTIDE TREATMENT OF NEW PTS W/ ACROMEGALY

$575M01FY2000RRNIH

Massachusetts General Hospital, Boston MA

Investigators

Linked publications & trials

Paper 39414844 Paper 39386517 Paper 38816203 Paper 38741246 Paper 38278947 Paper 38204926 Paper 37978826 Paper 37292813 Paper 37233759 Paper 37226675 Paper 36933679 Paper 36712107 Paper 36650173 Paper 36280384 Paper 35562076 Paper 35453142 Paper 35019976 Paper 34753805 Paper 34637524 Paper 34496463 Paper 34320286 Paper 33707304 Paper 33627633 Paper 33597215 Paper 33479058 Paper 33178459 Paper 33168654 Paper 33106254 Paper 33071178 Paper 33044802 Paper 33002231 Paper 32861645 Paper 32845968 Paper 32541385 Paper 32404950 Paper 32388179 Paper 32310273 Paper 32193296 Paper 32134326 Paper 32128240 Paper 32085906 Paper 32066692 Paper 32064729 Paper 31898874 Paper 31886931 Paper 31780185 Paper 31709648 Paper 31685489 Paper 31505070 Paper 31418516 Paper 31404238 Paper 31393564 Paper 31338998 Paper 31167889 Paper 31131339 Paper 31118516 Paper 31100122 Paper 30967435 Paper 30900413 Paper 30898204 Paper 30817009 Paper 30804324 Paper 30624677 Paper 30455329 Paper 30421851 Paper 30325779 Paper 30283035 Paper 29950175 Paper 29936086 Paper 29758564 Paper 29697830 Paper 29659886 Paper 29601406 Paper 29545462 Paper 29427697 Paper 29424780 Paper 29398050 Paper 29326107 Paper 29246363 Paper 29226174 Paper 29157731 Paper 29086498 Paper 29053861 Paper 29031905 Paper 28940967 Paper 28930079 Paper 28768705 Paper 28695142 Paper 28678345 Paper 28664624 Paper 28593722 Paper 28378429 Paper 28239652 Paper 28152193 Paper 27870507 Paper 27803118 Paper 27797678 Paper 27732336 Paper 27595918 Paper 27549584

Abstract

This is a phase II/III, open, multicentre study in which patients with acromegaly will receive IPSTYL over a period of up to sixteen weeks. Patients who are well controlled and have GH < 2.5 ng/ml following two injections of IPSTYL given at 14-day intervals, will receive in total 6 injections of IPSTYL every 14 days, for a minimum of 12 weeks. Patients who fail to respond sufficiently after the first two injections of IPSTYL when given at a 14 day interval, will receive three injections at 10-day intervals. These patients will, after having received their fifth injection, be re-evaluated. Patients who are controlled and exhibit GH < 2.5 ng/ml and IGF-1 values normalized, or have GH >2.5 ng/ml or elevated IGF-1 values but have symptomatic improvement, will continue in the study and receive a further six IPSTYL injections at 10-day intervals, for a total of 11 injections.

View original record on NIH RePORTER →